Drug updated on 11/9/2023

Dosage FormTablet (oral; 5 mg, 10 mg, 15 mg, 20 mg)
Drug ClassOrexin receptor antagonists
Ongoing and Completed


  • For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Product Monograph / Prescribing Information

Document TitleYearSource
Belsomra (suvorexant) Prescribing Information.2023Merck & Co., Rahway, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.2022Frontiers in Psychiatry
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.2022The Lancet
Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis. 2022Psychogeriatrics
Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.2022Sleep medicine reviews
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.2021Journal of Managed Care + Speciality Pharmacy
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis. 2021Sleep Medicine Reviews
Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis.2021Sleep Advances
Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: a systematic review.2021Journal of Sleep Research
Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis.2020Journal of Psychiatric Research
Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review.2019European Journal of Clinical Pharmacology

Clinical Practice Guidelines